EP0921723A1 - Charge et decharge de protecteurs a permeation pour la cryopreservation de cellules, de tissus et d'organes par vitrification - Google Patents
Charge et decharge de protecteurs a permeation pour la cryopreservation de cellules, de tissus et d'organes par vitrificationInfo
- Publication number
- EP0921723A1 EP0921723A1 EP97928712A EP97928712A EP0921723A1 EP 0921723 A1 EP0921723 A1 EP 0921723A1 EP 97928712 A EP97928712 A EP 97928712A EP 97928712 A EP97928712 A EP 97928712A EP 0921723 A1 EP0921723 A1 EP 0921723A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- protectant
- solute
- sample
- mol
- permeating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000011068 loading method Methods 0.000 title claims abstract description 49
- 238000004017 vitrification Methods 0.000 title claims description 55
- 238000005138 cryopreservation Methods 0.000 title claims description 13
- 210000000056 organ Anatomy 0.000 title description 6
- 239000000243 solution Substances 0.000 claims abstract description 76
- 239000000523 sample Substances 0.000 claims abstract description 38
- 238000000034 method Methods 0.000 claims abstract description 30
- 230000006378 damage Effects 0.000 claims abstract description 24
- 239000012472 biological sample Substances 0.000 claims abstract description 18
- 239000000310 rehydration solution Substances 0.000 claims abstract description 11
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 78
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 70
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 30
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 27
- -1 an aldose monosaccharide Chemical class 0.000 claims description 20
- 150000001720 carbohydrates Chemical class 0.000 claims description 17
- 235000014633 carbohydrates Nutrition 0.000 claims description 17
- 150000001413 amino acids Chemical class 0.000 claims description 15
- 150000005846 sugar alcohols Chemical class 0.000 claims description 14
- 230000003247 decreasing effect Effects 0.000 claims description 10
- 208000007976 Ketosis Diseases 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 7
- 150000007513 acids Chemical class 0.000 claims description 7
- 150000002016 disaccharides Chemical class 0.000 claims description 7
- 150000004676 glycans Chemical class 0.000 claims description 7
- 150000002337 glycosamines Chemical class 0.000 claims description 7
- 229920001223 polyethylene glycol Polymers 0.000 claims description 7
- 229920001282 polysaccharide Polymers 0.000 claims description 7
- 239000005017 polysaccharide Substances 0.000 claims description 7
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 claims description 6
- 229960003237 betaine Drugs 0.000 claims description 5
- CDAISMWEOUEBRE-UHFFFAOYSA-N inositol Chemical compound OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims description 5
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 claims 4
- 150000001412 amines Chemical class 0.000 claims 4
- 210000004027 cell Anatomy 0.000 description 70
- 230000018044 dehydration Effects 0.000 description 33
- 238000006297 dehydration reaction Methods 0.000 description 33
- 230000007423 decrease Effects 0.000 description 18
- 210000002216 heart Anatomy 0.000 description 18
- 238000011067 equilibration Methods 0.000 description 17
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 15
- 229930195725 Mannitol Natural products 0.000 description 15
- 239000000594 mannitol Substances 0.000 description 15
- 235000010355 mannitol Nutrition 0.000 description 15
- 229960001855 mannitol Drugs 0.000 description 15
- 231100000419 toxicity Toxicity 0.000 description 13
- 230000001988 toxicity Effects 0.000 description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 230000003834 intracellular effect Effects 0.000 description 11
- 230000003204 osmotic effect Effects 0.000 description 11
- 235000001014 amino acid Nutrition 0.000 description 10
- 235000018102 proteins Nutrition 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 230000000254 damaging effect Effects 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 210000002257 embryonic structure Anatomy 0.000 description 8
- 210000003743 erythrocyte Anatomy 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 231100000331 toxic Toxicity 0.000 description 6
- 230000002588 toxic effect Effects 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 210000000172 cytosol Anatomy 0.000 description 5
- 230000035515 penetration Effects 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 4
- 206010018910 Haemolysis Diseases 0.000 description 4
- 102000001554 Hemoglobins Human genes 0.000 description 4
- 108010054147 Hemoglobins Proteins 0.000 description 4
- 239000012839 Krebs-Henseleit buffer Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 230000008014 freezing Effects 0.000 description 4
- 238000007710 freezing Methods 0.000 description 4
- 235000013922 glutamic acid Nutrition 0.000 description 4
- 239000004220 glutamic acid Substances 0.000 description 4
- 230000004217 heart function Effects 0.000 description 4
- 230000008588 hemolysis Effects 0.000 description 4
- 230000000149 penetrating effect Effects 0.000 description 4
- 230000010412 perfusion Effects 0.000 description 4
- 238000004321 preservation Methods 0.000 description 4
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 230000005779 cell damage Effects 0.000 description 3
- 208000037887 cell injury Diseases 0.000 description 3
- 231100000045 chemical toxicity Toxicity 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 210000000805 cytoplasm Anatomy 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000036571 hydration Effects 0.000 description 3
- 238000006703 hydration reaction Methods 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 150000004001 inositols Chemical class 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 210000001938 protoplast Anatomy 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 241000255601 Drosophila melanogaster Species 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 108010077895 Sarcosine Proteins 0.000 description 2
- 241000209056 Secale Species 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229940093740 amino acid and derivative Drugs 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- RXKJFZQQPQGTFL-UHFFFAOYSA-N dihydroxyacetone Chemical compound OCC(=O)CO RXKJFZQQPQGTFL-UHFFFAOYSA-N 0.000 description 2
- 230000002706 hydrostatic effect Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 238000003260 vortexing Methods 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- NTBYIQWZAVDRHA-KCDKBNATSA-N (2s,3s,4r,5s)-2-amino-3,4,5-trihydroxyhexanal Chemical compound C[C@H](O)[C@@H](O)[C@@H](O)[C@H](N)C=O NTBYIQWZAVDRHA-KCDKBNATSA-N 0.000 description 1
- BJHIKXHVCXFQLS-UHFFFAOYSA-N 1,3,4,5,6-pentahydroxyhexan-2-one Chemical compound OCC(O)C(O)C(O)C(=O)CO BJHIKXHVCXFQLS-UHFFFAOYSA-N 0.000 description 1
- ZAQJHHRNXZUBTE-UHFFFAOYSA-N 1,3,4,5-tetrahydroxypentan-2-one Chemical compound OCC(O)C(O)C(=O)CO ZAQJHHRNXZUBTE-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- YIJFIIXHVSHQEN-UHFFFAOYSA-N 3-Aminocaproic acid Chemical compound CCCC(N)CC(O)=O YIJFIIXHVSHQEN-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-WHZQZERISA-N D-aldose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-WHZQZERISA-N 0.000 description 1
- HEBKCHPVOIAQTA-QWWZWVQMSA-N D-arabinitol Chemical compound OC[C@@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-QWWZWVQMSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- MNQZXJOMYWMBOU-VKHMYHEASA-N D-glyceraldehyde Chemical compound OC[C@@H](O)C=O MNQZXJOMYWMBOU-VKHMYHEASA-N 0.000 description 1
- FBPFZTCFMRRESA-ZXXMMSQZSA-N D-iditol Chemical compound OC[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-ZXXMMSQZSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 241000270288 Gekko Species 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- XSISQURPIRTMAY-UHFFFAOYSA-N Hydroxyethyl glycine Chemical compound NCC(=O)OCCO XSISQURPIRTMAY-UHFFFAOYSA-N 0.000 description 1
- SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 206010062575 Muscle contracture Diseases 0.000 description 1
- FOUZISDNESEYLX-UHFFFAOYSA-N N-hydroxyethyl glycine Natural products OCCNCC(O)=O FOUZISDNESEYLX-UHFFFAOYSA-N 0.000 description 1
- 235000017284 Pometia pinnata Nutrition 0.000 description 1
- 240000007653 Pometia tomentosa Species 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- JVWLUVNSQYXYBE-UHFFFAOYSA-N Ribitol Natural products OCC(C)C(O)C(O)CO JVWLUVNSQYXYBE-UHFFFAOYSA-N 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 150000001323 aldoses Chemical class 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- SRBFZHDQGSBBOR-STGXQOJASA-N alpha-D-lyxopyranose Chemical compound O[C@@H]1CO[C@H](O)[C@@H](O)[C@H]1O SRBFZHDQGSBBOR-STGXQOJASA-N 0.000 description 1
- 229940124277 aminobutyric acid Drugs 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000003205 diastolic effect Effects 0.000 description 1
- 229940120503 dihydroxyacetone Drugs 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 150000002386 heptoses Chemical class 0.000 description 1
- 150000002402 hexoses Chemical class 0.000 description 1
- 230000000887 hydrating effect Effects 0.000 description 1
- NBZBKCUXIYYUSX-UHFFFAOYSA-N iminodiacetic acid Chemical compound OC(=O)CNCC(O)=O NBZBKCUXIYYUSX-UHFFFAOYSA-N 0.000 description 1
- 230000000266 injurious effect Effects 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 150000002584 ketoses Chemical class 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000036316 preload Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 235000013930 proline Nutrition 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- HEBKCHPVOIAQTA-ZXFHETKHSA-N ribitol Chemical compound OC[C@H](O)[C@H](O)[C@H](O)CO HEBKCHPVOIAQTA-ZXFHETKHSA-N 0.000 description 1
- 229940043230 sarcosine Drugs 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 235000014393 valine Nutrition 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/10—Preservation of living parts
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/10—Preservation of living parts
- A01N1/12—Chemical aspects of preservation
- A01N1/122—Preservation or perfusion media
- A01N1/125—Freeze protecting agents, e.g. cryoprotectants or osmolarity regulators
Definitions
- the present invention relates to non-toxic loading and unloading of permeating protectants that is required for the cryopreservation of biological specimens
- Ice formation at low temperatures can be avoided only if samples are sufficiently dehydrated.
- Dehydration is also known as a common cell damaging factor. The damaging effect of the dehydration increases with increasing concentration of vitrification solution and depends strongly on whether the vitrification solution contains permeating protectants such as dimethylsulfoxide
- DMSO ethylene glycol
- EG ethylene glycol
- propylene glycol glycerol
- glycerol glycerol
- dehydration does not mean decrease in the cell volume, which actually may be very damaging (Marymen, 1967, 1970) .
- dehydration means removal of water, or increase in the osmotic pressure. Erroneous use of this term has resulted in several misconceptions. For example, as described below, dehydration by itself is not a strong damaging factor. Dehydration may even be a protective factor, if performed according to the present invention.
- Damage of cells during dehydration in concentrated solutions of non-permeating solutes is believed to be caused by hydration forces occurring between biological macromolecules and membranes when distances between them become small as a result of dehydration Bryant and Wolfe (1992) .
- permeating protectant protects against cell dehydration because intracellular protectant diminishes these forces. Therefore, some amount of intracellular protectants are required to protect cells during dehydration to high osmotic pressures.
- vitrification of larger and more complex specimens has not been achieved yet primarily because of the toxic effect of highly concentrated solutions containing permeating protectants. These concentrated solutions are needed to prevent ice formation in complex specimens during cooling and warming. Therefore, one should consider the dependence of cell injury on the time of equilibration in vitrification solution to better understand the mechanism(s) of toxicity. For successful preservation by vitrification, vitrification solution should more effectively diminish both ice formation in the cytosol and extracellular volumes, and toxic effects associated with equilibration (dehydration) of the specimen in concentrated vitrification solution.
- Fahy et al . (1990) found that biochemical studies of the toxicity to date have not met the basic criteria required for demonstrating mechanisms of toxicity. This actually means that the direct chemical toxicity of typical permeating protectants (ethylene glycol, propylene glycol, glycerol and DMSO) is small. The inventor agrees with the conclusion of Fahy et al . (1990) that present concepts of protectant toxicity are in need of serious revision.
- This toxic effect is not related to the increase in intracellular osmotic pressure or biochemical toxicity of protectant because after water efflux from loaded cells, the osmotic pressure and concentration of protectant inside cells is approximately equal to that outside the cells.
- Timasheff (1993) criticized the belief that protectants form some sort of coating (a shell) that protects proteins from denaturation during cryopreservation. His criticism was based on the articles of Gekko and Timasheff (1981) , Lee and Timasheff (1981) , and other publications reporting that protectants excluded from the surface of proteins. The inventor (Bronshtein, 1995) submitted that the above conclusion of Timasheff and his co-workers is questionable for two reasons. First, the thermodynamic equilibrium in the dialysis experiments of Timasheff and his co-workers cannot be obtained if the hydrostatic pressure inside the dialysis bag is equal to the pressure outside the bag.
- Steponkus et al . (1992) have shown that decreasing osmolarity of the vitrification solution allows one to decrease the damaging effect of dehydration in vitrification solution if the dehydration time is several minutes or less. However, to obtain cell survival after cryopreservation, one should successfully vitrify both the extracellular solution and the cytosol. For this reason, Steponkus et al . (1992) suggested that the better protectant for the loading step is one that allows stable vitrification of cytosol after dehydration in vitrification solution with lower osmolarity. This suggestion was a reflection of a general belief that the presence of protectants inside cells helps to vitrify cytosol.
- the method should allow for controlled permeation of protectants into the samples during long-term contact of the samples with the vitrification solution.
- Both loading and unloading methods, vitrification and rehydration solutions should allow for superior survival of the cryopreserved sample.
- the present invention is directed to a method for minimizing toxic effects of loading and unloading biological specimens with permeating protectants.
- the method includes the steps of loading the sample by contacting the sample with a solution comprising a permeating protectant and a non-permeating co-solute that limits the amount of the protectant that penetrates into cells of the biological specimen.
- decreasing the ability of the protectant to enter cells of the biological specimen is achieved most effectively by adding non-penetrating co-solutes that effectively decrease the chemical potential of permeating protectants in the extracellular solution.
- the more co-solute that is added the less amount of protectant penetrates into the cells; however, some minimum amount of protectant inside the cells is required to protect the cells against dehydration.
- the concentration of the co-solutes that can be added is limited.
- the maximum concentration of co-solutes that can be added to the extracellular solution, to limit penetration of protectant inside cells, depends on the minimum amount of protectant required to protect cells against dehydration.
- the maximum concentration of co-solutes can be found experimentally for every specific combination of permeating protectants, osmotic pressure of the extracellular solution, and type of co-solute.
- the method also includes gradual or stepwise loading (unloading) of permeating protectants with simultaneous increase (decrease) in concentration of permeating protectants and non-permeating co-solutes.
- concentration of non- permeating co-solutes should be the maximum possible concentration that still does not damage cells.
- Co-solutes that decrease the chemical potential of penetrating Protectants or protectants in aqueous solutions include, but are not limited to:
- Amino acids glycine, alanine, glutamic acid, proline, valine, hydroxy- 1 -proline , betaaminopropionic acid, aminobutyric acid, beta-aminocaproic acid, aminoisobutyric acid, N-methylglycine, norvaline, and others that are soluble in water in concentration greater than 0.1 mol/1, and derivatives of amino acids (sarcosine, iminodiacetic acid, hydroxyethyl glycine, etc.) that are soluble in water in concentration >0.1 mol/1.
- Betaines betaine and other betaines that are soluble in water in concentration greater than 0.1 mol/1.
- Carbohydrates a) Monosaccharides (aldoses and ketoses) : glyceraldehyde, lyxose, ribose, xylose, galactose, glucose, hexose, mannose talose, heptose, dihydroxyacetone, pentulose, hexulose, heptulose, octulose, etc., and their derivatives; b) Amino sugars: D-ribose, 3-amino-3 -deoxy- , chitosamine, fucosamine, etc.
- Alditols and inositols glycerol , erythritol, arabinitol , ribitol, mannitol, iditol, betitol, inositol , etc . ; d) Aidonic, uronic, and aldaric acids that are soluble in water in concentration >0.1 mol/1; and e) disaccharides and polysaccharides (sucrose, trehalose, etc.) .
- Amino acids most effectively decrease the chemical potential of permeating protectants in aqueous solutions.
- the invention allows one to significantly increase concentrations of vitrification solution and the times of loading, cell equilibration in the vitrification solution, and unloading, without increasing cell damage. This allows one to solve many problems occurring during loading of organs with protectants and subsequent cooling by decreasing gradients of osmotic pressure within the sample. This is a very important matter, because if a portion of cells in the sample is less dehydrated it may freeze at low temperatures and be damaged.
- Hydration of the cells after cryopreservation and washing out of protectant (unloading) is achieved by equilibration of the specimens (perfusion with, in the case of organs) in solutions of the same protectant with lower osmotic pressures, but still containing the maximum concentration of the co-solutes (amino acids, betaines or carbohydrates) that do not damage cells.
- the change of concentration during unloading may be gradual or stepwise. This will speed up efflux of protectant and limit the increase of the cell's volume during rehydration. This is an important issue because the increase in cell volume, more than the initial cell volume, may damage the cells.
- Fig. 1 shows a plot of the effect of co-solutes on toxicity of 60% ethylene glycol vitrification solution on red blood cells.
- the present invention is directed toward improving low temperature preservation of cells, multicellular specimens and organs by vitrification.
- samples should be substantially dehydrated.
- the dehydration damages cells because of large repulsive forces between macromolecules that occur inside cells.
- a small amount of protectant should be present inside cells in order to decrease these forces.
- the amount of protectant inside the cells should be kept as low as possible to decrease the toxic effect of vitrification solution and to increase the stability of the amorphous state inside the cells at low temperatures . This can be achieved by including non-penetrating co-solutes (amino acids, betaines, sugars, etc.) in the vitrification solution in concentrations from 0.1 - 0.7 mol/1.
- intracellular protectant should be removed from the cells and exchanged for water.
- the inventor believes that damage during rehydration occurs because of an increase in cell volume to more than the initial cell volume, when cells are transferred from vitrification solution to washing (rehydration) solutions.
- rehydration solutions amino acids, betaines, carbohydrates, or other non-penetrating, co-solutes that effectively decrease the chemical potential of permeating protectants in aqueous solutions.
- the co-solutes are used in concentrations from 0.1 - 0.7 mol/1. Higher co-solute concentrations will more effectively limit the mass of intracellular protectant, however, when this mass gets very small the dehydrated cells may be damaged.
- the method for preserving a biological sample comprising the step of loading the sample by contacting the sample with a solution comprising a permeating protectant and a co-solute that decreases the ability of the protectant to enter cells of the biological specimen.
- the protectant is one of a group of common permeating protectants including, but not limited to, dimethylsulfoxide, ethylene glycol, propylene glycol and glycerol.
- the co-solute is one of a number of the following classes of compounds including, but not limited to, amino acids and derivatives thereof soluble in water in concentration greater than 0.1 mol/1, betaines soluble in water in concentration greater than 0.1 mol/1, carbohydrates and sugar alcohols, wherein the carbohydrates are selected from the group consisting of aldose monosaccharides, ketose monosaccharides, amino sugars, alditols, inositols, aidonic, uronic and aldaric acids soluble in water in concentrations of greater than 0.1 mol/1, disaccharides and polysaccharides .
- the total concentration of non-permeating co-solutes in the vitrification solution is preferably between 0.1 and 0.7 mol/1 and is equal to a maximum possible concentration that does not damage cells.
- the method of the present invention involves both gradual and/or stepwise loading of permeating protectants with simultaneous increase in concentration of permeating protectants and non-permeating co-solutes.
- concentration of non-permeating co-solutes should be the maximum possible concentration that still does not damage the biological specimen.
- the loading step is performed in two or more stages of contacting the sample with increasingly higher concentrations of permeating protectant and co-solute.
- the loading step is performed by simultaneously increasing concentrations of both the protectant and the co-solute from initial concentrations to final concentrations according to a desired profile.
- the initial concentration of permeating protectant is zero.
- the initial concentration of co-solute is preferably zero, but may be greater than zero as long as the co-solute does not damage the sample.
- the final concentration of co- solute may be determined empirically depending on the nature of the specimen and the choice and concentration of protectant .
- the unloading of the protectant can be performed in a gradual or step-wise manner.
- the only limitation in the profile of the simultaneous increase in protectant and co-solute concentration during loading is that the concentrations of the respective elements remain in an optimal proportion to minimize toxic effect of high concentrations of protectants.
- the increase in concentration of the protectant and co-solute may be performed manually or mechanically and may be accomplished stepwise or according to a desired profile.
- the shape of the profile curve may be linear or non-linear, depending upon empirical optimization of the profile for a specific cell type.
- the rehydration or unloading step is directed to the replacement of protectant in the preserved sample with water.
- the step of unloading the sample is performed by contacting the sample with a rehydration solution which can be an aqueous solution lacking the protectant (having smaller concentration of the protectant) such that the protectant is removed from the cells of the sample.
- a rehydration solution which can be an aqueous solution lacking the protectant (having smaller concentration of the protectant) such that the protectant is removed from the cells of the sample.
- the sample is unloaded in a manner opposite that of the loading step.
- the rehydration solution includes a co-solute and a protectant and the unloading step is performed by simultaneously decreasing concentrations of both the protectant and the co-solute from initial concentrations to final concentrations according to a desired profile.
- the initial concentrations of both the protectant and the co- solute may be identical to or smaller than the final concentrations thereof, respectively, in the loading process.
- the protectant and the co-solute used during unloading are the same as those used during loading of the same sample.
- the protectant and co-solute of the rehydration or unloading solution are selected from the same groups of compounds used in the loading or vitrification solutions.
- the protectant is one of a group of common permeating protectants including, but not limited to, dimethylsulfoxide, ethylene glycol, propylene glycol and glycerol.
- the co-solute is one of a number of the following classes of compounds including, but not limited to, amino acids and derivatives thereof soluble in water in concentration greater than 0.1 mol/1, betaines soluble in water in concentration greater than 0.1 mol/1, carbohydrates and sugar alcohols, wherein the carbohydrates are selected from the group consisting of aldose monosaccharides, ketose monosaccharides, amino sugars, alditols, inositols, aidonic, uronic and aldaric acids soluble in water in concentrations of greater than 0.1 mol/1, disaccharides and polysaccharides.
- the total concentration of non-permeating co-solutes in the unloading solutions is preferably between 0.1 and 0.7 mol/1 and is equal to a maximum possible concentration that does not damage cells.
- the unloading step involves both gradual and/or stepwise unloading of permeating protectants with a simultaneous decrease in the concentration of the permeating protectants and non- permeating co-solutes.
- the initial concentration of non- permeating co-solutes should be the maximum possible concentration that still does not damage the biological specimen.
- the unloading step is also performed in two or more stages of contacting the sample with increasingly lower concentrations of permeating protectant and non-permeating co-solute.
- the unloading step is performed by simultaneously decreasing concentrations of both the protectant and the co-solute from initial concentrations to final concentrations according to a desired profile.
- the initial concentrations of protectant and co-solute is preferably the same as the final concentrations in the loading (vitrification) solution.
- the final concentration of permeating protectant is zero.
- the final concentration of co-solute may be greater than zero as long as the co-solute does not damage the sample cells.
- the loading of the protectant can be performed in a gradual or stepwise manner.
- the only limitation in the profile of the simultaneous decrease in protectant and co- solute concentrations during unloading is that the concentrations of the respective elements remain in an optimal proportion to minimize toxicity and to maximize viability on rehydration.
- the decrease in concentrations of the protectant and co-solute may be performed manually or mechanically and may be accomplished stepwise or according to a desired profile.
- the shape of the profile curve may be linear or non-linear, depending on empirical optimization of the profile for a specific cell type.
- EXAMPLE 1 Gradual Loading and Unloading of Rat Heart with Dimethylsulfoxide (DMSO) .
- DMSO Dimethylsulfoxide
- the heart was excised and immediately immersed in ice-cold Krebs- Henseleit buffer (KHB) , which contained (in mM) : 118 NaCl, 11 glucose, 25 NaHC0 3 , 4.7 KC1, 1.2 MgS0 4 , 1.2 KH 2 P0 4 , 0.5 Na-EDTA, and 2.5 CaCl 2 ⁇
- KHB Krebs- Henseleit buffer
- the aorta was cannulated and the heart retrograde perfused at 70 mm Hg for 9 min. with 36.5°C KHB equilibrated with 95% 0 2 /% C0 2 .
- the perfusion was continued for 2 min. at 60 mm Hg with CP-llE saturated with 100% 0 2 .
- composition of CP-llE (in mM) was: 125 NaCl, 7 glucose, 1.2 KH 2 P0 4 , 10 mannitol, 15 MgS0 4 , 14 KC1, 10 Hepes, 0.02 EDTA, 0.28 CaCl 2 , pH 7.5.
- Loading and removal of DMSO and manni tol After
- CP-llE flush the arrested heart was transferred to a perfusion apparatus (Fig. 1) . Both CP-11EB and CP- HE+DMSO+mannitol were bubbled constantly with 100% 0 2 . Perfusate was delivered via an aortic cannula by a peristaltic pump at a flow rate of 1 ml/min. Two experiments were performed at room temperature. Experiment 0: The heart was gradually loaded with 30 wt% DMSO and immediately unloaded. No co-solutes were used. A linear gradient of 0 to 30% DMSO was generated using a gradient maker. DMSO gradient was controlled by the duration of infusion (or the total volume of solution infused) . Loading time was 30 min. During the 30 min.
- Experiment 1 The heart was gradually loaded with 30 wt% DMSO and immediately unloaded. A linear gradient of both 0 to 30% DMSO and 0 to 3% mannitol was generated using a gradient maker. DMSO gradient was controlled by the duration of infusion (or the total volume of solution infused) . Loading time was 30 min. During the 30 min. loading, the rate of increase in concentration of the solution was 1% DMSO/min. and 0.075% mannitol/min. Unloading began right after the end of loading. Unloading time was 60 min. During the 60 min. unloading, a gradient of decreasing DMSO concentration was 0.5 wt%/min. , the final concentration of mannitol was 1 wt%.
- Experiment 2 The heart was gradually loaded with 30 wt% DMSO during 30 min, then perfused 30 min. with 30% DMSO + 3% mannitol, and then unloaded during 60 min. A linear gradient of both 0 to 30% DMSO and 0 to 3% mannitol was generated using a gradient maker. DMSO gradient was controlled by the duration of infusion (or the total volume of solution infused) . During the 30 min. loading, the rate of increase in concentration was 1% DMSO/min. and 0.075% mannitol/min. During the 60 min. unloading, a gradient of decreasing DMSO concentration was 0.5 wt%/min, the final concentration of mannitol was 1 wt%.
- Cardiac function was assessed by working mode reperfusion with KHB at 11 mm Hg preload and 70 mm Hg after load.
- Heart rate HR, beats/min
- AF and CF, ml/min. aortic and coronary flow
- CO AF+CF, ml/min.
- systolic and diastolic aortic pressure mm Hg
- Coronary vascular resistance and work were calculated according to Neely et al . , 1967 (Neely et al . "Effect of Pressure Development on Oxygen Consumption by the Isolated Rat Heart” . Am. J. Physiology, 212:804-12, 1967) .
- Step 1 100 ⁇ l of blood were mixed with 100 ⁇ l of 30 wt% EG + 0.9 wt% NaCl. Equilibration time 10 min.
- Step 2 1000 ⁇ l of vitrification solution vitrification solution containing mixture of 60 wt% EG + 0.9 wt% NaCl with different amounts of glutamic acid monosodium Salt (GA) per gram of Vitrification solution were slowly (during 3-5 min.) added to the mixture obtained after Step 1.
- G glutamic acid monosodium Salt
- Step 1 After 60 min. equilibration in vitrification solution erythrocytes were centrifuged down
- Step 2 After 10 min. of equilibration, above the erythrocytes were centrifuged down again, then, 0.5 ml of supernatant was removed from each sample, and 0.5 ml of 3 wt% GA + 0.9 wt% NaCl were added to each sample. Then the samples were mixed by vortexing and were equilibrated 10 min.
- erythrocytes were centrifuged down again and 0.5 ml of supernatant was collected from each sample.
- Concentration of free hemoglobin in supernatants collected from the samples after equilibration in Vitrification solution, first and second step of unloading was used to characterize the erythrocyte damage (hemolysis) .
- the concentration of free hemoglobin was measured using 390 Turner spectrophotometer (at 550nm wavelength) after adding 0.5 ml of supernatant to 3 ml of water.
- the hemolysis was measured as a ratio of hemoglobin concentration in the supernatants to the hemoglobin concentration in the mixture of 41.7 ⁇ l of blood with 3.5 ml water that was taken as 100% hemolysis.
- Steponkus P.L., Langis, R. and Fujikawa, S. 1992. Cryopreservation of plant tissues by vitrification. In: Advances in Low- Temperature Biology, Vol. 1, edited by P.L. Steponkus. pp. 1-61. JAI Press, Ltd., London.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Dentistry (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
L'invention concerne un procédé pour la cryopréservation d'un échantillon biologique, y compris la charge progressive ou par étape de l'échantillon avec un protecteur à perméation, procédé sans lequel on met en contact l'échantillon avec des solutions renfermant le protecteur et aussi un co-soluté sans perméation qui limite la quantité de protecteur pénétrant dans les cellules du spécimen biologique. Le procédé consiste en outre à décharger (sous forme de réhydratation) progressivement ou par étape l'échantillon par mise au contact d'une ou de plusieurs solutions réhydratantes en abaissant graduellement la concentration du protecteur et du co-soluté, de manière à éliminer le protecteur dans les cellules de l'échantillon. La concentration du co-soluté pendant les opérations de charge et de décharge doit avoir la valeur maximum atteignable sans pour autant endommager l'échantillon aussi bien à température ambiante qu'aux températures inférieures à 0°.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1863896P | 1996-05-29 | 1996-05-29 | |
US18638P | 1996-05-29 | ||
PCT/US1997/009207 WO1997045010A1 (fr) | 1996-05-29 | 1997-05-29 | Charge et decharge de protecteurs a permeation pour la cryopreservation de cellules, de tissus et d'organes par vitrification |
Publications (1)
Publication Number | Publication Date |
---|---|
EP0921723A1 true EP0921723A1 (fr) | 1999-06-16 |
Family
ID=21788996
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP97928712A Withdrawn EP0921723A1 (fr) | 1996-05-29 | 1997-05-29 | Charge et decharge de protecteurs a permeation pour la cryopreservation de cellules, de tissus et d'organes par vitrification |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0921723A1 (fr) |
JP (1) | JP2001517204A (fr) |
AU (1) | AU3290097A (fr) |
CA (1) | CA2256714A1 (fr) |
WO (1) | WO1997045010A1 (fr) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2379111C (fr) * | 1999-07-13 | 2011-07-26 | Thomson Licensing S.A. | Systeme de gestion des erreurs dans les informations specifiques a des programmes dans un decodeur video |
US6869757B2 (en) * | 2000-07-31 | 2005-03-22 | 21St Century Medicine, Inc. | Advantageous carrier solution for vitrifiable concentrations of cryoprotectants, and compatible cryoprotectant mixtures |
US7250292B2 (en) * | 2000-01-26 | 2007-07-31 | 21St Century Medicine | Hypertonic reduction of chilling injury |
US7094601B2 (en) | 2000-05-16 | 2006-08-22 | The General Hospital Corporation | Microinjection of cryoprotectants for preservation of cells |
US20020045156A1 (en) * | 2000-05-16 | 2002-04-18 | Mehmet Toner | Microinjection of cryoprotectants for preservation of cells |
DE102004030285B4 (de) * | 2004-06-23 | 2007-08-02 | Franz Lahnsteiner | Gefrierkonservierung von Eiern und Embryonen von Fischen |
WO2012067240A1 (fr) | 2010-11-19 | 2012-05-24 | セーレン株式会社 | Solution de stockage vitrifiée pour des cellules |
CN109042628A (zh) * | 2018-09-21 | 2018-12-21 | 洛阳未羊生物科技有限公司 | 一种羊膜组织的冻存方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4980277A (en) * | 1987-10-16 | 1990-12-25 | Cultor Ltd. | Cryoprotectant solution and method |
US5071741A (en) * | 1988-04-18 | 1991-12-10 | Cryolife, Inc. | Cryoprotective agent and its use in cryopreservation of cellular matter |
US5595866A (en) * | 1994-05-27 | 1997-01-21 | Methodist Hospital Of Indiana, Inc. | Step-wise method to remove cryoprotectant from sperm |
-
1997
- 1997-05-29 WO PCT/US1997/009207 patent/WO1997045010A1/fr not_active Application Discontinuation
- 1997-05-29 AU AU32900/97A patent/AU3290097A/en not_active Abandoned
- 1997-05-29 CA CA002256714A patent/CA2256714A1/fr not_active Abandoned
- 1997-05-29 JP JP54295497A patent/JP2001517204A/ja not_active Ceased
- 1997-05-29 EP EP97928712A patent/EP0921723A1/fr not_active Withdrawn
Non-Patent Citations (1)
Title |
---|
See references of WO9745010A1 * |
Also Published As
Publication number | Publication date |
---|---|
AU3290097A (en) | 1998-01-05 |
JP2001517204A (ja) | 2001-10-02 |
WO1997045010A1 (fr) | 1997-12-04 |
CA2256714A1 (fr) | 1997-12-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NL193971C (nl) | Perfusaat voor het conserveren van organen. Waterige samenstelling voor het conserveren en bewaren van organen. | |
US10687525B2 (en) | Enhancement of cell cryopreservation with glycolipids | |
JP4031044B2 (ja) | 細胞凍結保存培地中のアラビノガラクタンの使用 | |
Costanzo et al. | Survival mechanisms of vertebrate ectotherms at subfreezing temperatures: applications in cryomedicine | |
US20020102720A1 (en) | Preservation solution | |
Jacobsen et al. | Effect of cooling and warming rate on glycerolized rabbit kidneys | |
KR100855354B1 (ko) | 관류세척 보존 용액 | |
AU2017340511B2 (en) | Systems and methods for natural cryoprotectants for preservation of cells | |
WO2001095717A2 (fr) | Procede de cryopreservation reposant sur l'utilisation d'une composition cryoprotectrice a base de propanediol et de solution vectrice | |
SE505499C2 (sv) | Förvaringslösning för organ och vävnad eller delar därav från människor och djur innehållande kalcium och nitroglycerin, användning därav samt förfarande för förvaring därmed | |
US20150111193A1 (en) | Methods and solutions for tissue preservation | |
EP0921723A1 (fr) | Charge et decharge de protecteurs a permeation pour la cryopreservation de cellules, de tissus et d'organes par vitrification | |
US20060240399A1 (en) | Long-term shelf preservation of cells and multicellular specimens by vitrification | |
Jesus et al. | Natural deep eutectic systems—A new era of cryopreservation | |
CN102948412A (zh) | 用于保存组织和器官的水溶液 | |
US20040018482A1 (en) | Loading and unloading of permeating protectants for cell, tissue, and organ cryopreservation by vitrification | |
Costanzo et al. | Biophysical and physiological responses promoting freeze tolerance in vertebrates | |
EP0932337A1 (fr) | Solutions de vitrification servant a conserver a long terme des cellules, des tissus, des organes et des organismes | |
Wilson et al. | Preservation solutions for solid organ transplantation | |
KR100304594B1 (ko) | 이식용 장기 및 혈액세포 보존제의 조성물 | |
CA2996859C (fr) | Agent de conservation pour organes ou tissus et procede de conservation pour organes ou tissus | |
JPS6127901A (ja) | 生体を保存する方法 | |
Tonev et al. | Human Serum Albumin And Hydroxy Ethyl Starch Are Protective Alone And In Combination For Human Hematopoietic Stem Cells Stored at-80ºC With 5% Dimethylsulphoxide | |
Pegg et al. | Permeation of rabbit kidneys with cryoprotective agents | |
Brockbank et al. | Society for Cryobiology1'2 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19981209 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: UNIVERSAL PRESERVATION TECHNOLOGIES, INC. |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20021203 |